中国当代医药
中國噹代醫藥
중국당대의약
China Modern Medicine
2015年
26期
132-134
,共3页
李光彩%付存玉%张志刚%姚宗芹
李光綵%付存玉%張誌剛%姚宗芹
리광채%부존옥%장지강%요종근
坎地沙坦%扩张性心肌病%和肽素
坎地沙坦%擴張性心肌病%和肽素
감지사탄%확장성심기병%화태소
Candesartan%Dilated cardiomyopathy%Copeptin
目的:研究坎地沙坦对扩张性心肌病患者血清和肽素的影响。方法选择2013年1月~2014年6月在我院就诊的42例扩张性心肌病患者,将其随机分为坎地沙坦组(27例)和常规治疗组(15例),另设年龄、性别与之匹配的28例健康者作为对照组。采用酶联免疫分析法检测3组患者的血清和肽素水平,另外,常规治疗组和坎地沙坦组在治疗2周后复查。结果扩张性心肌病患者血清和肽素水平较健康者明显升高,差异有统计学意义(P<0.05)。治疗后,坎地沙坦组血清和肽素水平较治疗前明显下降,差异有统计学意义(P<0.05),但常规治疗组血清和肽素水平较治疗前差异无统计学意义(P跃0.05)。结论扩张性心肌病心力衰竭患者血清和肽素水平较健康者升高,而坎地沙坦能明显降低扩张性心肌病心力衰竭患者的血清和肽素水平。
目的:研究坎地沙坦對擴張性心肌病患者血清和肽素的影響。方法選擇2013年1月~2014年6月在我院就診的42例擴張性心肌病患者,將其隨機分為坎地沙坦組(27例)和常規治療組(15例),另設年齡、性彆與之匹配的28例健康者作為對照組。採用酶聯免疫分析法檢測3組患者的血清和肽素水平,另外,常規治療組和坎地沙坦組在治療2週後複查。結果擴張性心肌病患者血清和肽素水平較健康者明顯升高,差異有統計學意義(P<0.05)。治療後,坎地沙坦組血清和肽素水平較治療前明顯下降,差異有統計學意義(P<0.05),但常規治療組血清和肽素水平較治療前差異無統計學意義(P躍0.05)。結論擴張性心肌病心力衰竭患者血清和肽素水平較健康者升高,而坎地沙坦能明顯降低擴張性心肌病心力衰竭患者的血清和肽素水平。
목적:연구감지사탄대확장성심기병환자혈청화태소적영향。방법선택2013년1월~2014년6월재아원취진적42례확장성심기병환자,장기수궤분위감지사탄조(27례)화상규치료조(15례),령설년령、성별여지필배적28례건강자작위대조조。채용매련면역분석법검측3조환자적혈청화태소수평,령외,상규치료조화감지사탄조재치료2주후복사。결과확장성심기병환자혈청화태소수평교건강자명현승고,차이유통계학의의(P<0.05)。치료후,감지사탄조혈청화태소수평교치료전명현하강,차이유통계학의의(P<0.05),단상규치료조혈청화태소수평교치료전차이무통계학의의(P약0.05)。결론확장성심기병심력쇠갈환자혈청화태소수평교건강자승고,이감지사탄능명현강저확장성심기병심력쇠갈환자적혈청화태소수평。
Objective To explore the impact of candesartan on serum copeptin in patients with dilated cardiomyopathy. Methods 42 patients with dilated cardiomyopathy admitted into our hospital from January 2013 to June 2014 were se-lected and randomly divided into candesartan treatment group(n=27) and routine treatment group(n=15).28 healthy per-sons with matched age and gender was selected as control group.By enzyme-linked immunosorbent assay,serum copeptin levels in three groups were detected.The routine treatment group and candesartan treatment group was reexam-ined two weeks after treatment. Results The level of serum copeptin in patients with dilated cardiomyopathy was greatly increased compared with the healthy control group with a statistical difference(P<0.05).After using candesartan,the level of serum copeptin in candesartan treatment group was significantly decreased compared with that before treatment,the difference was significant (P<0.05),but the level of serum copeptin in routine treatment group was indicated a declined tendency compared with that before,the difference was no significant (P>0.05). Conclusion The serum copeptin level in patients with dilated cardiomyopathy and heart failure is in an increase,and candesartan can significantly reduce the serum copeptin level in these patients.